CASTLE BIOSCIENCES INC

Castle Biosciences is a molecular diagnostics company that develops and commercializes gene expression profile (GEP) and spatial-omics tests for dermatologic cancers, Barrett's esophagus, and psychiatric conditions. The company's diagnostic portfolio addresses multiple clinical specialties, with particular focus on skin cancer and gastroenterology markets. Key offerings include DecisionDx-Melanoma and DecisionDx-SCC, which provide risk stratification for melanoma and squamous cell carcinoma patients; MyPath Melanoma, a diagnostic test for challenging melanocytic lesions; and DecisionDx-UM, a risk assessment tool for uveal melanoma. The company also markets TissueCypher, a spatial-omics test designed to predict progression of Barrett's esophagus to esophageal cancer.

Beyond oncology diagnostics, Castle Biosciences operates in the mental health segment through IDgenetix, a pharmacogenomic test that guides medication selection for patients with conditions including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, and ADHD. The tests are distributed primarily to dermatologists, gastroenterologists, and mental health specialists.

Incorporated in Delaware in 2007, the company is headquartered in Friendswood, Texas, with approximately 823 full-time employees. Castle Biosciences is publicly traded on Nasdaq.